Abstract
A genome-wide CRISPR screen reveals a pivotal role for TRPM4 in cell death and immune activation following treatment with diverse necrosis-inducing anticancer therapies, which could facilitate development of necrosis-based cancer immunotherapies.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have